Answers are grounded in this paper and cite their sources.
Neutropenia is a mild and transient manifestation of neonatal lupus syndrome (NLS) in the second or third month of life. The authors describe a newborn with an early-onset severe neutropenia due to anti-Ro/SSA. In the second day of life, neutropenia has been treated with recombinant human granulocyte colony-stimulating factor (rh-G-CSF). This is the first case in which rh-G-CSF was used in NLS, and the authors studied the pharmacologic action of the drug in relationship to the pathophysiology of NLS.
No takes yet. Share an insight, caveat, or question.
Zuppa et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: